
## Jingchuan Guo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2298146/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet, The, 2020, 396, 2019-2082.	13.7	327
2	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. Journal of the American Society of Nephrology: JASN, 2019, 30, 2000-2016.	6.1	135
3	Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis. Journal of the American Pharmacists Association: JAPhA, 2022, 62, 1816-1822.e2.	1.5	82
4	Increased Aortic Calcification Is Associated With Arterial Stiffness Progression in Multiethnic Middle-Aged Men. Hypertension, 2017, 69, 102-108.	2.7	51
5	Developing and validating a machine-learning algorithm to predict opioid overdose in Medicaid beneficiaries in two US states: a prognostic modelling study. The Lancet Digital Health, 2022, 4, e455-e465.	12.3	20
6	Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease. British Journal of Clinical Pharmacology, 2016, 82, 352-361.	2.4	17
7	Optimal Blood Pressure Thresholds for Minimal Coronary Artery Disease Risk in Type 1 Diabetes. Diabetes Care, 2019, 42, 1692-1699.	8.6	17
8	The role of coronary artery calcification testing in incident coronary artery disease risk prediction in type 1 diabetes. Diabetologia, 2019, 62, 259-268.	6.3	16
9	Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes. JAMA Network Open, 2022, 5, e227705.	5.9	15
10	The role of initial and longitudinal change in blood pressure on progression of arterial stiffness among multiethnic middle-aged men. Journal of Hypertension, 2017, 35, 111-117.	0.5	9
11	Greater progression of coronary artery calcification is associated with clinically relevant cognitive impairment in type 1 diabetes. Atherosclerosis, 2019, 280, 58-65.	0.8	9
12	Costs and outcomes of "intermediate―vs "minimal―care for youthâ€onset type 1 diabetes in six countries. Pediatric Diabetes, 2020, 21, 628-636.	2.9	9
13	Association of alcohol consumption and aortic calcification in healthy men aged 40–49 years for the ERA JUMP Study. Atherosclerosis, 2018, 268, 84-91.	0.8	6
14	Prognostic Significance of Pulse Pressure and Other Blood Pressure Components for Coronary Artery Disease in Type 1 Diabetes. American Journal of Hypertension, 2019, 32, 1075-1081.	2.0	6
15	Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: groupâ€based multiâ€trajectory models. Addiction, 2022, 117, 1982-1997.	3.3	6
16	Excess mortality and cardiovascular disease risk in type 1 diabetes. Lancet, The, 2019, 393, 985.	13.7	5
17	Are novel glucoseâ€lowering agents' cardiorenal benefits generalizable to individuals of <scp>Black</scp> race? A metaâ€trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes, Obesity and Metabolism, 2022, 24, 154-159.	4.4	5
18	Effect of the COVID-19 pandemic on adversity in individuals receiving anticoagulation for atrial fibrillation: A nationally representative administrative health claims analysis. American Heart Journal Plus, 2022, 13, 100096.	0.6	5

JINGCHUAN GUO

#	Article	IF	CITATIONS
19	Mediation analysis for estimating cardioprotection of longitudinal RAS inhibition beyond lowering blood pressure and albuminuria in type 1 diabetes. Annals of Epidemiology, 2020, 41, 7-13.e1.	1.9	4
20	Comparison of Oral Anticoagulant Use and Stroke Risk Among Older Adults Newly-Diagnosed Atrial Fibrillation Living in Urban-Versus-Rural Areas. American Journal of Cardiology, 2020, 130, 64-69.	1.6	4
21	Newer drug treatments for type 2 diabetes. BMJ, The, 2021, 373, n1171.	6.0	4
22	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care, 2022, 45, 1007-1012.	8.6	4
23	Newer <scp>glucoseâ€lowering</scp> drugs and risk of dementia: A <scp>metaâ€analysis</scp> of cardiovascular outcome trials. Journal of the American Geriatrics Society, 2022, 70, 2719-2722.	2.6	4
24	Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare. Diabetes Care, 2022, 45, 1814-1821.	8.6	4
25	Serum long-chain n-3 polyunsaturated fatty acids and aortic calcification in middle-aged men: The population-based cross-sectional ERA-JUMP study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 837-846.	2.6	3
26	Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes. Diabetes Care, 2022, 45, e32-e33.	8.6	3
27	Income disparities in driving distance to health care infrastructure in the United States: a geographic information systems analysis. BMC Research Notes, 2022, 15, .	1.4	3
28	Data on alcohol consumption and coronary artery calcification among asymptomatic middle-aged men for the ERA-JUMP study. Data in Brief, 2018, 17, 1091-1098.	1.0	2
29	Occupational Patterns of Opioid-Related Overdose Deaths Among Arizona Medicaid Enrollees, 2008–2017. Journal of General Internal Medicine, 2020, 35, 2210-2213.	2.6	2
30	Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries. American Journal of Cardiovascular Drugs, 2021, 21, 581-583.	2.2	2
31	Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study. Journal of Diabetes and Its Complications, 2022, 36, 108132.	2.3	2
32	Changes in predicted opioid overdose risk over time in a state Medicaid program: a groupâ€based trajectory modeling analysis. Addiction, 2022, 117, 2254-2263.	3.3	2
33	Left ventricular systolic dysfunction predicts long-term major microvascular complication outcomes in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications (EDC) study of childhood onset diabetes. Journal of Diabetes and Its Complications, 2018, 32, 298-304.	2.3	1
34	Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1500-1502.	0.9	1
35	Racial and Urban-Rural Difference in the Frequency of Ischemic Stroke as Initial Manifestation of Atrial Fibrillation. Frontiers in Public Health, 2021, 9, 780185.	2.7	1
36	Reply. Journal of Hypertension, 2017, 35, 1326-1327.	0.5	0

#	Article	IF	CITATIONS
37	The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010–2018. Current Medical Research and Opinion, 2021, 37, 1-6.	1.9	ο
38	Simulating Colorectal Cancer Trials Using Real-World Data. JCO Clinical Cancer Informatics, 2022, , .	2.1	0